Randomised clinical trial: Ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting - Randomised clinical study subset data Academic Article uri icon

Overview

MeSH Major

  • Gastrointestinal Agents
  • Gastroparesis
  • Macrocyclic Compounds
  • Nausea
  • Vomiting

abstract

  • TZP-101 substantially reduced the frequency and severity of nausea and vomiting as well as overall gastroparesis symptoms. The results are consistent with gastrointestinal motility effects of TZP-101, supporting further investigation of TZP-101 in the management of severe gastroparesis.

publication date

  • March 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1111/j.1365-2036.2010.04567.x

PubMed ID

  • 21214610

Additional Document Info

start page

  • 679

end page

  • 88

volume

  • 33

number

  • 6